Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.
Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S, Kamolratanakul S, Sivakorn C, Narakorn P, Surichan S, Prangpratanporn S, Puksuriwong S, Lamola S, Mercer LD, Raghunandan R, Sun W, Liu Y, Carreño JM, Scharf R, Phumratanaprapin W, Amanat F, Gagnon L, Hsieh CL, Kaweepornpoj R, Khan S, Lal M, McCroskery S, McLellan J, Mena I, Meseck M, Phonrat B, Sabmee Y, Singchareon R, Slamanig S, Suthepakul N, Tcheou J, Thantamnu N, Theerasurakarn S, Tran S, Vilasmongkolchai T, White JA, Bhardwaj N, Garcia-Sastre A, Palese P, Krammer F, Poopipatpol K, Wirachwong P, Hjorth R, Innis BL. Pitisuttithum P, et al. Among authors: tcheou j. EClinicalMedicine. 2022 Mar 8;45:101323. doi: 10.1016/j.eclinm.2022.101323. eCollection 2022 Mar. EClinicalMedicine. 2022. PMID: 35284808 Free PMC article.
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
Carreño JM, Alshammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, Sominsky LA, Clark JJ, Adelsberg DC, Bielak DA, Gonzalez-Reiche AS, Dambrauskas N, Vigdorovich V; PSP-PARIS Study Group; Srivastava K, Sather DN, Sordillo EM, Bajic G, van Bakel H, Simon V, Krammer F. Carreño JM, et al. Among authors: tcheou j. Nature. 2022 Feb;602(7898):682-688. doi: 10.1038/s41586-022-04399-5. Epub 2021 Dec 31. Nature. 2022. PMID: 35016197
Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer.
Mack PC, Gomez JE, Rodilla AM, Carreño JM, Hsu CY, Rolfo C, Meshulami N, Moore A, Brody RI, King JC, Treatman J, Lee S, Raskin A, Srivastava K, Gleason CR, de Miguel-Perez D; PARIS/PSP study group; Tcheou J, Bielak D, Acharya R, Gerber DE, Rohs N, Henschke CI, Yankelevitz DF, Simon V, Minna JD, Bunn PA Jr, García-Sastre A, Krammer F, Shyr Y, Hirsch FR. Mack PC, et al. Among authors: tcheou j. Cancer Cell. 2022 Jun 13;40(6):575-577. doi: 10.1016/j.ccell.2022.04.012. Epub 2022 Apr 20. Cancer Cell. 2022. PMID: 35504289 Free PMC article. No abstract available.
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
Duc Dang A, Dinh Vu T, Hai Vu H, Thanh Ta V, Thi Van Pham A, Thi Ngoc Dang M, Van Le B, Huu Duong T, Van Nguyen D, Lawpoolsri S, Chinwangso P, McLellan JS, Hsieh CL, Garcia-Sastre A, Palese P, Sun W, Martinez JL, Gonzalez-Dominguez I, Slamanig S, Manuel Carreño J, Tcheou J, Krammer F, Raskin A, Minh Vu H, Cong Tran T, Mai Nguyen H, Mercer LD, Raghunandan R, Lal M, White JA, Hjorth R, Innis BL, Scharf R. Duc Dang A, et al. Among authors: tcheou j. Vaccine. 2022 Jun 9;40(26):3621-3632. doi: 10.1016/j.vaccine.2022.04.078. Epub 2022 May 14. Vaccine. 2022. PMID: 35577631 Free PMC article. Clinical Trial.
Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.
Katz Sand I, Gnjatic S, Krammer F, Tuballes K, Carreño JM, Satyanarayan S, Filomena S, Staker E, Tcheou J, Miller A, Fabian M, Safi N, Nichols J, Patel J, Krieger S, Tankou S, Horng S, Klineova S, Beck E, Merad M, Lublin F. Katz Sand I, et al. Among authors: tcheou j. Mult Scler Relat Disord. 2023 Feb;70:104486. doi: 10.1016/j.msard.2022.104486. Epub 2022 Dec 28. Mult Scler Relat Disord. 2023. PMID: 36628884 Free PMC article.
An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination.
Carreño JM, Raskin A, Singh G, Tcheou J, Kawabata H, Gleason C, Srivastava K, Vigdorovich V, Dambrauskas N, Gupta SL, González Domínguez I, Martinez JL, Slamanig S, Sather DN, Raghunandan R, Wirachwong P, Muangnoicharoen S, Pitisuttithum P, Wrammert J, Suthar MS, Sun W, Palese P, García-Sastre A, Simon V, Krammer F. Carreño JM, et al. Among authors: tcheou j. Sci Transl Med. 2023 Feb 15;15(683):eabo2847. doi: 10.1126/scitranslmed.abo2847. Epub 2023 Feb 15. Sci Transl Med. 2023. PMID: 36791207 Free article.
Binding and Avidity Signatures of Polyclonal Sera From Individuals With Different Exposure Histories to Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Vaccination, and Omicron Breakthrough Infections.
Singh G, Abbad A, Tcheou J, Mendu DR, Firpo-Betancourt A, Gleason C, Srivastava K, Cordon-Cardo C, Simon V, Krammer F, Carreño JM. Singh G, et al. Among authors: tcheou j. J Infect Dis. 2023 Aug 31;228(5):564-575. doi: 10.1093/infdis/jiad116. J Infect Dis. 2023. PMID: 37104046 Free PMC article.
20 results